(S)-(+)-Dimethindene maleate: Practical Research Workflow

(S)-(+)-Dimethindene maleate is a small-molecule antagonist supplied as the maleate salt. The product dossier identifies it as (S)-N,N-dimethyl-2-(3-(1-(pyridin-2-yl)ethyl)-1H-inden-2-yl)ethanamine maleate, CAS 136152-65-3, with a molecular weight of 408.5 g/mol and a stated purity of 98.00%. The dossier describes selective affinity for the M2 muscarinic acetylcholine receptor, reduced interaction with M1, M3, and M4, and antagonist activity at the histamine H1 receptor.

No directly matched paper evidence is available for this product entry. Accordingly, the workflow below uses the supplied product specifications and conservative laboratory practices rather than assigning potency, efficacy, receptor occupancy, or biological outcomes that have not been provided.

What This Product Solves

The main practical problem is how to perturb M2-associated pharmacology without automatically treating the compound as a broad muscarinic blocker. The dossier positioning makes this compound relevant to targeted receptor-selectivity profiling and to experiments involving autonomic regulation research, cardiovascular physiology studies, and respiratory system function research.

Its H1 antagonist activity is an important design constraint. A change in tissue, cell, or organ-level response after treatment cannot be assigned to the muscarinic acetylcholine receptor signaling pathway solely from the use of this compound. H1-related effects should be considered explicitly, particularly in systems containing histamine-responsive cells or tissues. A suitable design therefore includes a defined M2 hypothesis, a vehicle control, and, where interpretation depends on subtype discrimination, comparison with M1, M3, M4, and H1-relevant controls.

This compound is better suited to a targeted muscarinic M2 receptor antagonist workflow than to experiments requiring broad muscarinic blockade. It can help structure a receptor-specific perturbation experiment, but the dossier does not establish complete selectivity, a functional response profile, or a universal concentration range.

Protocol Parameters

The parameters below distinguish product-dossier values from workflow recommendations. The aqueous solubility value is a handling specification, not a recommended assay concentration or a potency estimate.

• Assay: aqueous stock preparation; Value: ≥20.45 mg/mL in water; Applicability: initial solution preparation and solvent selection; Rationale: the reported water solubility supports water as a starting solvent, but the final working concentration must be established for the specific assay; Evidence basis: product dossier.
• Assay: molar concentration calculation; Value: 408.5 g/mol; Applicability: conversion of weighed maleate salt to molar assay concentrations; Rationale: using the salt molecular weight avoids errors when preparing receptor or tissue experiments on a molar basis; Evidence basis: product dossier.
• Assay: material qualification; Value: 98.00% purity; Applicability: reagent release and batch documentation; Rationale: purity should be recorded when comparing experiments or interpreting concentration-dependent data, without treating the value as proof of biological selectivity; Evidence basis: product dossier.
• Assay: receptor selectivity profiling; Value: study-defined concentration series in µM or another validated unit; Applicability: M2-focused assays with H1 and other muscarinic counter-assessment; Rationale: a predefined series is preferable to selecting a dose from solubility alone and allows response, cytotoxicity, and selectivity boundaries to be evaluated separately; Evidence basis: workflow recommendation, not a product specification.
• Assay: solid and solution storage; Value: desiccated at room temperature for the solid; use prepared solutions promptly; Applicability: routine reagent handling; Rationale: the dossier does not recommend long-term solution storage, so repeated reuse of an old preparation should be avoided unless independently validated; Evidence basis: product dossier.

Workflow Setup and QC Checklist

1. Define the receptor question before dosing

Specify whether the experiment is testing M2-linked signaling, comparing muscarinic subtypes, or evaluating a tissue response in which H1 activity may contribute. If the endpoint is intended to support an M2 interpretation, include an H1-aware control strategy and document why the selected model is informative. For a concise handling overview, see (S)-(+)-Dimethindene Maleate: Practical Guide. It complements this article by emphasizing controlled in vitro or ex vivo use and prompt handling of prepared solutions.

2. Verify identity and calculate the preparation

Record the product name, SKU B6734, CAS number, lot information, stated purity, and molecular weight before weighing. Use 408.5 g/mol for calculations involving the maleate salt. Record the actual mass, solvent, preparation date, operator, and calculated concentration in the laboratory record. Do not silently substitute the free-base molecular weight or assume that a salt-equivalent concentration has the same meaning as a free-base concentration.

3. Prepare and inspect the solution

Use water as an initial solvent because the dossier reports solubility of at least 20.45 mg/mL in water. Prepare only the amount needed for the planned experiment, inspect the solution for visible particulates or unexpected changes, and document any deviation from the intended appearance. If the assay requires another solvent, verify compatibility with the cells, tissue, receptor preparation, and detection system before use. Keep the vehicle composition identical across treated and control conditions.

4. Build controls around the dual target profile

• Include untreated and vehicle-matched controls.
• Use a study-defined concentration series rather than one unvalidated concentration.
• Where subtype attribution matters, include M1, M3, and M4 comparison conditions or an appropriate orthogonal assay.
• Assess H1-relevant interference when the model contains histamine-responsive components.
• Predefine the primary endpoint, acceptable assay variability, exclusion rules, and replicate structure before unblinding results.

For a more narrowly targeted discussion of M2 antagonist experiments, see (S)-(+)-Dimethindene maleate in M2 Muscarinic Antagonist Workflows. It complements the present QC checklist with guidance on using targeted rather than broad muscarinic blockade.

Common Failure Modes and Fixes

Assigning every phenotype to M2

Problem: A response is interpreted as M2-specific without considering H1 antagonism or residual interaction with other muscarinic subtypes. Fix: include H1-aware controls and, where feasible, subtype comparison experiments. Describe the result as compound-associated unless the control structure supports a narrower conclusion.

Using solubility as a biological dose

Problem: The maximum reported aqueous solubility is treated as a recommended working concentration. Fix: use the solubility value only to plan stock preparation. Establish assay concentrations from model-specific validation, including signal window, viability, nonspecific effects, and analytical range.

Reusing solutions after extended storage

Problem: A prepared solution is stored for convenience and later used without stability verification. Fix: prepare solutions promptly before use, follow the dossier recommendation against long-term solution storage, and document preparation and use times. If storage is unavoidable, perform an independent stability check rather than assuming retained activity.

Incorrect salt-form conversion

Problem: The free-base formula or molecular weight is used for a maleate-salt preparation. Fix: calculate with the supplied 408.5 g/mol value and retain the salt form in all sample labels and calculations.

Vehicle-related assay artifacts

Problem: Treated wells receive a different solvent volume or composition from controls. Fix: match vehicle conditions across all groups and verify that the vehicle itself does not alter the receptor readout, cell state, tissue tone, or detection chemistry.

Scope and Limitations

This guide is a workflow framework, not a substitute for directly matched literature evidence. The supplied information does not provide IC₅₀, EC₅₀, K_i, residence time, receptor occupancy, functional efficacy, species dependence, cell-line performance, tissue concentration, or validated stability data. Those parameters must not be inferred from the product description, molecular weight, purity, or water solubility.

The dossier describes reduced interaction with M1, M3, and M4, but reduced interaction is not equivalent to absolute subtype selectivity. The concurrent H1 antagonist activity also limits interpretation in systems where histamine signaling contributes to the endpoint. This compound should not be selected when the experimental objective requires a broad muscarinic antagonist, a purely M2-exclusive probe, or long-term solution stability without additional validation.

The material is supplied for scientific research use only and is not intended for diagnostic, therapeutic, or other medical applications.

Conclusion

(S)-(+)-Dimethindene maleate can be incorporated into M2-focused pharmacological studies when its dual M2/H1 antagonist profile is built into the design. Use the documented salt molecular weight, purity, aqueous solubility, and storage instructions for reagent control; use separate workflow validation to establish working concentrations and interpretability. The most defensible experiments combine fresh, documented preparations with vehicle matching, subtype-aware controls, and explicit acknowledgment that no directly matched paper evidence is available for this product entry.